Usefulness of serum CCL2 as prognostic biomarker in prostate cancer: a long-term follow-up study.
Iwamoto H, Izumi K, Nakagawa R, Toriumi R, Aoyama S, Shimada T, Kano H, Makino T, Kadomoto S, Yaegashi H, Kawaguchi S, Nohara T, Shigehara K, Kadono Y, Mizokami A.
Iwamoto H, et al. Among authors: nakagawa r.
Jpn J Clin Oncol. 2022 Nov 3;52(11):1337-1344. doi: 10.1093/jjco/hyac102.
Jpn J Clin Oncol. 2022.
PMID: 35726158